<DOC>
	<DOCNO>NCT01298362</DOCNO>
	<brief_summary>The purpose study identify combine impact bone loss well incidence bone fracture woman estrogen receptor ( ER ) -positive , early breast cancer treat aromatase inhibitor ( AI ) either first line therapy maintenance therapy initial treatment chemotherapy , real life clinical setting Greece .</brief_summary>
	<brief_title>Impact Chemotherapy Followed Aromatase Inhibitors Bone Health Women With ER-positive Early Breast Cancer</brief_title>
	<detailed_description>Subjects ER-positive early breast cancer treat AIs either first line therapy maintenance therapy initial treatment chemotherapy . The total study duration 24 month comprise recruitment period 12 month follow-up period 12 month participate subject . The primary outcome variable mean percentage variation lumbar spine ( LS ) bone mineral density ( BMD ) 12 month follow - period . Measurements take chemotherapy end 12 month follow - period .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Bone Diseases</mesh_term>
	<mesh_term>Aromatase Inhibitors</mesh_term>
	<criteria>Provision inform consent . Age ≥ 40 year . Female patient ERpositive early breast cancer , receive therapy third generation AI either first line hormonal treatment maintenance therapy firstline anthracycline and/or taxanebased chemotherapy period longer 1 month ( 4 week ) prior inclusion present study . Women render postmenopausal prior chemotherapy commencement least 12 month last menstrual period . For subject amenorrheic &lt; 12 month ( include patient underwent hysterectomy , receive estrogen replacement therapy ( ERT ) / hormone replacement therapy ( HRT ) , must serum follicle stimulate hormone ( FSH ) ≥50 IU/L commencement AI therapy . Patients available data lumbar spine total hip bone mineral density ( BMD ) prior chemotherapy initiation well commencement AI therapy . Prior administration endocrine therapy include tamoxifen . Chemotherapyinduced menopause . Evidence disease know interfere bone metabolism , hyperparathyroidism , hyperthyroidism , osteomalacia , chronic liver disease , renal failure , hypercortisolism , malabsorption , immobilization . Evidence bone metastasis evidence abnormal clinical laboratory parameter assess clinically significant investigator . Involvement plan conduct study . Participation clinical study within period 3 month prior study related procedure . Patients normal bone density mild osteopenia ( T score &gt; = 2 site ) treatment oral intravenous bisphosphonates . Vitamin D calcium supplement allow . Patients severe osteopenia osteoporosis ( T score &lt; = 2 site ) treatment intravenous bisphosphonates . Oral bisphosphonates , Vitamin D calcium supplement allow . Patients treatment oral intravenous bisphosphonates chemotherapy commencement . Patients stop hormonereplacement therapy ( HRT ) less 3 month chemotherapy commencement . Patients receive neoadjuvant treatment .</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>